WO2020259675A1 - 神经激肽-1拮抗剂 - Google Patents

神经激肽-1拮抗剂 Download PDF

Info

Publication number
WO2020259675A1
WO2020259675A1 PCT/CN2020/098460 CN2020098460W WO2020259675A1 WO 2020259675 A1 WO2020259675 A1 WO 2020259675A1 CN 2020098460 W CN2020098460 W CN 2020098460W WO 2020259675 A1 WO2020259675 A1 WO 2020259675A1
Authority
WO
WIPO (PCT)
Prior art keywords
compound
alkyl
aryl
heteroaryl
cycloalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/CN2020/098460
Other languages
English (en)
French (fr)
Chinese (zh)
Inventor
黄建
祝令建
邹洋
唐应刚
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jiangsu Hengrui Medicine Co Ltd
Shanghai Shengdi Pharmaceutical Co Ltd
Shanghai Senhui Medicine Co Ltd
Original Assignee
Jiangsu Hengrui Medicine Co Ltd
Shanghai Shengdi Pharmaceutical Co Ltd
Shanghai Senhui Medicine Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to AU2020308397A priority Critical patent/AU2020308397B2/en
Priority to EP20831251.2A priority patent/EP3991730A4/en
Priority to KR1020227003091A priority patent/KR102940508B1/ko
Priority to MX2021015827A priority patent/MX2021015827A/es
Priority to JP2021577929A priority patent/JP7702887B2/ja
Priority to CA3144247A priority patent/CA3144247A1/en
Priority to CN202410285183.XA priority patent/CN118324811A/zh
Priority to US17/623,205 priority patent/US12421260B2/en
Application filed by Jiangsu Hengrui Medicine Co Ltd, Shanghai Shengdi Pharmaceutical Co Ltd, Shanghai Senhui Medicine Co Ltd filed Critical Jiangsu Hengrui Medicine Co Ltd
Priority to CN202080040881.3A priority patent/CN113905735B/zh
Priority to BR112021026554A priority patent/BR112021026554A2/pt
Publication of WO2020259675A1 publication Critical patent/WO2020259675A1/zh
Anticipated expiration legal-status Critical
Priority to JP2025071172A priority patent/JP2025111616A/ja
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • C07F9/65615—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings containing a spiro condensed ring system of the formula where at least one of the atoms X or Y is a hetero atom, e.g. S
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/26—Acyclic or carbocyclic radicals, substituted by hetero rings

Definitions

  • the present disclosure relates to an antagonist of the neuropeptide neurokinin-1 (NK1 or NK-1) receptor.
  • Tachykinin is a peptide ligand for neurokinin receptors.
  • Neurokinin receptors such as NK1, NK2 and NK3, are involved in various biological processes. They can be found in the nervous and circulatory system of mammals and in surrounding tissues. Therefore, the modulation of such receptors has been studied for potential treatment or prevention of various diseases in mammals.
  • Typical neurokinin receptor antagonists and their uses include: US5760018 (1998) (pain, inflammation, migraine and vomiting), US5620989 (1997) (pain, nociception and inflammation), WO95/19344 (1995), WO 94/13639 (1994) and WO 94/10165 (1994).
  • NK1 receptor antagonists include: Wu et al., Tetrahedron 56, 3043-3051 (2000); Rombouts et al., Tetrahedron Letters 42, 7397-7399 (2001); and Rogiers et al., Tetrahedron 57, 8971 8981 (2001).
  • US7049320 provides an effective, selective, and beneficial therapeutic and pharmacological properties and good metabolic stability of NK1 antagonist (5S, 8S)-8-[ ⁇ (1R)-1-(3,5 -Bis-(trifluoromethyl)phenyl)-ethoxy ⁇ -methyl]-8-phenyl-1,7-diazaspiro[4.5]dec-2-one (compound of formula I), which The compound can take the form of a free base or a pharmaceutically acceptable salt form, and is a formulation suitable for parenteral administration.
  • US9101615 provides a prodrug of a compound of formula I, that is, a prodrug and a salt thereof in which the hydrogen of the free amine (or two amines) of the compound of formula I is replaced by a group selected from -Y and -X, wherein Y is selected from -P( O)(OH) 2 , -S(O) n1 R 1 , -C(O)(C 1-6 alkyl)X, -C(O)(C 1-6 alkyl)(aryl),- C(O)OR 4 ; X is selected from -NR 2 R 3 , -P(O)(OH) 2 or -S(O) n1 R 1 ; R 1 is H or C 1-6 alkyl; R 2 is H or C 1-6 alkyl; R 3 is H or C 1-6 alkyl; R 4 is H or C 1-6 alkyl; n1 is 0-4.
  • the prodrug can be used in a suitable liquid formulation (including
  • Drug hemolysis is caused by the massive destruction of red blood cells caused by immune factors after the drug enters the human body.
  • hemolysis such as anemia, jaundice, soy sauce and urine appears.
  • Drug-induced hemolytic anemia can be divided into the following three types: (1) drug-induced immunity, which leads to antibody-mediated hemolytic reactions; (2) drugs acting on red blood cells with genetic enzyme defects (such as G6PD deficiency); (3) The hemolytic reaction of drugs to abnormal hemoglobin.
  • the key to treating this disease is to stop the use of related drugs and control the occurrence of hemolysis to prevent complications.
  • CN102573475 discloses an improved prescription containing polyethylene glycol 15-hydroxystearate and medium chain triglycerides.
  • the hemolysis of the pharmaceutical composition is still not completely resolved, even if the compound of formula I is prepared as a prodrug containing phosphate.
  • This application provides a new NK1 antagonist prodrug compound that is effective in treating various physiological disorders, symptoms and diseases with minimal side effects.
  • X is selected from hydrogen, heterocyclyl, aryl, heteroaryl, -C(O)OA m R 3 , -C(O)NR 4 A m R 3 , -A m [C(R 1 )( R 2 )]C(O)OA n R 3 , -A m OC(O)[C(R 1 )(R 2 )]A n R 3 , -A m C(O)NR 4 A n R 3 , -A m NR 4 C(O)A n R 3 or -A m R 5 , the heterocyclic group, aryl group or heteroaryl group is optionally selected by one or more selected from alkyl, cycloalkyl, alkoxy Group, hydroxyalkyl, alkenyl, alkynyl, aryl, heteroaryl, nitro, nitrile, hydroxyl, halogen, SR', NR'(R"), COOR' or CONR' or CON
  • Y is selected from hydrogen, -C(O)OA m R 3 , -C(O)NR 4 A m R 3 , -A m [C(R 1 )(R 2 )]C(O)OA n R 3 , -A m OC(O)[C(R 1 )(R 2 )]A n R 3 , -A m C(O)NR 4 A n R 3 , -A m NR 4 C(O)A n R 3 Or -A m R 5 ;
  • A is independently selected from -C(R 1 )(R 2 )(B) p -or -(B) q C(R 1 )(R 2 )-,
  • R 1 , R 2 or R 4 are each independently selected from hydrogen, alkyl, cycloalkyl, heterocyclyl, aryl or heteroaryl, said alkyl, cycloalkyl, heterocyclyl, aryl or hetero
  • the aryl group is optionally selected by one or more selected from alkyl, cycloalkyl, alkoxy, hydroxyalkyl, alkenyl, alkynyl, aryl, heteroaryl, nitro, nitrile, hydroxyl, halogen, SR ', NR'(R”), COOR' or CONR'(R”) replaced;
  • R 3 is selected from hydrogen, alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, poly(ethyleneoxyethyleneoxy) Poly(ethyleneoxy) OPO(R 6 ) 2 , PO(R 6 ) 2 , OSO 2 (R 6 ) 2 , SO 2 (R 6 ) 2 , OC(O)R 6 or C(O)OR 6 , the alkyl group, ring Alkyl, heterocyclyl, aryl or heteroaryl is optionally selected by one or more selected from alkyl, cycloalkyl, alkoxy, hydroxyalkyl, alkenyl, alkynyl, aryl, heteroaryl, Nitro, nitrile, hydroxyl, halogen, SR', NR'(R”), COOR' or CONR'(R”) substituted;
  • R 5 is selected from heterocyclic group, heteroaryl group, OSO 2 R 7 , OC(O)R 7 , SR', SO 2 R'or NR'(R”);
  • R 6 is each independently selected from hydrogen, hydroxy, alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, alkoxy, hydroxyalkyl or NR'(R”), the alkyl, hydroxy Alkyl, cycloalkyl, heterocyclyl, aryl or heteroaryl is optionally selected by one or more selected from alkyl, cycloalkyl, alkoxy, hydroxyalkyl, alkenyl, alkynyl, aryl, Heteroaryl, nitro, nitrile, hydroxyl, halogen, SR', NR'(R"), COOR' or CONR'(R”) substituted;
  • R 7 is each independently selected from alkyl, hydroxy, cycloalkyl, heterocyclyl, aryl, heteroaryl, hydroxyalkyl or NR'(R"), the alkyl, hydroxyalkyl, cycloalkyl , Heterocyclyl, aryl or heteroaryl optionally selected by one or more selected from alkyl, cycloalkyl, alkoxy, hydroxyalkyl, alkenyl, alkynyl, aryl, heteroaryl, nitro , Nitrile, hydroxyl, halogen, SR', NR'(R”), COOR' or CONR'(R”);
  • R'or R" are independently selected from hydrogen, hydroxyl, alkyl (preferably from C 1-12 alkyl, including but not limited to methyl, ethyl or isopropyl), alkoxy (preferably from C 1-12 Alkoxy), alkenyl, acyl;
  • B is each independently selected from O, N, SC(O)
  • n, o are each independently selected from 1-10, and can be 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10; p, q are each independently selected from 0 or 1;
  • X and Y are not hydrogen at the same time.
  • the compound represented by formula II of the present disclosure has better solubility than the parent drug formula I compound, and therefore, it is suitable for intravenous administration.
  • the aforementioned compounds after the aforementioned compounds are made into intravenous preparations and enter the human body, they degrade and release the parent drug under physiological conditions, delaying the release of the drug and prolonging the release period of the drug.
  • the compound represented by formula II wherein X is selected from hydrogen, heterocyclyl, aryl, heteroaryl, -C(O)O[C(R 1 )(R 2 )( O) p ] m R 3 , -C(O)NR 4 [C(R 1 )(R 2 )(O) p ] m R 3 , -[C(R 1 )(R 2 )(O) p ] m C(O)[C(R 1 )(R 2 )(O) p ] n R 3 , -[C(R 1 )(R 2 )(O) p ] m [C(R 1 )(R 2 )]C(O)[(O) q C(R 1 )(R 2 )] n R 3 , -[C(R 1 )(R 2 )(O) p ] m C(O)NR 4 [C (R 1 )
  • Y is selected from hydrogen, -C(O)O[C(R 1 )(R 2 )(O) p ] m R 3 , -C(O)NR 4 [C(R 1 )(R 2 )(O) p ] m R 3 , -[C(R 1 )(R 2 )(O) p ] m C(O)[C(R 1 )(R 2 )(O) p ] n R 3 , -[C( R 1 )(R 2 )(O) p ] m C(O)[(O) q C(R 1 )(R 2 )] n R 3 , -[C(R 1 )(R 2 )(O) p ] m C(O)NR 4 [C(R 1 )(R 2 )(O) p ] n R 3 or -[C(R 1 )(R 2 )(O) p ] m R 5
  • the compound represented by formula II wherein Y is selected from -C(O)O[C(R 1 )(R 2 )] m R 3 , -C(O)NR 4 [C (R 1 )(R 2 )] m R 3 , -[C(R 1 )(R 2 )O] m C(O)[C(R 1 )(R 2 )] n R 3 , -[C( R 1 )(R 2 )] m C(O)[OC(R 1 )(R 2 )] n R 3 , -[C(R 1 )(R 2 )N] m C(O)[C(R 1 )(R 2 )] n R 3 , [C(R 1 )(R 2 )N] m C(O)[OC(R 1 )(R 2 )] n R 3 , [C(R 1 )(R 2 )N] m C(O)[OC(R 1 )
  • the compound represented by formula II wherein Y is selected from -C(O)O[C(R 1 )(R 2 )] m R 3 , -C(O)NR 4 [C (R 1 )(R 2 )] m R 3 , -[C(R 1 )(R 2 )O] m C(O)[C(R 1 )(R 2 )] n R 3 , -[C( R 1 )(R 2 )] m C(O)[OC(R 1 )(R 2 )] n R 3 , -[C(R 1 )(R 2 )N] m C(O)[C(R 1 )(R 2 )] n R 3 , [C(R 1 )(R 2 )N] m C(O)[OC(R 1 )(R 2 )] n R 3 , [C(R 1 )(R 2 )N] m C(O)[OC(R 1 )
  • the compound represented by formula II wherein Y is selected from -C(O)O[C(R 1 )(R 2 )] m R 3 , -C(O)NR 4 [C (R 1 )(R 2 )] m R 3 , -[C(R 1 )(R 2 )O] m C(O)[C(R 1 )(R 2 )] n R 3 , -[C( R 1 )(R 2 )] m C(O)[OC(R 1 )(R 2 )] n R 3 , -[C(R 1 )(R 2 )N] m C(O)[C(R 1 )(R 2 )] n R 3 , [C(R 1 )(R 2 )N] m C(O)[OC(R 1 )(R 2 )] n R 3 , [C(R 1 )(R 2 )N] m C(O)[OC(R 1 )
  • the compound represented by formula II wherein Y is selected from -C(O)O[C(R 1 )(R 2 )]R 3 , -C(O)NR 4 [C( R 1 )(R 2 )]R 3 , -[C(R 1 )(R 2 )O]C(O)[C(R 1 )(R 2 )]R 3 , -[C(R 1 )( R 2 )]C(O)[OC(R 1 )(R 2 )]R 3 , -[C(R 1 )(R 2 )N]C(O)[C(R 1 )(R 2 )] R 3 , [C(R 1 )(R 2 )N]C(O)[OC(R 1 )(R 2 )]R 3 , [C(R 1 )(R 2 )N]C(O)[ NC(R 1 )(R 2 )]R 3 , -[
  • the compound represented by formula II wherein Y is selected from -C(O)O[C(R 1 )(R 2 )] 2 R 3 , -C(O)NR 4 [C (R 1 )(R 2 )] 2 R 3 , -[C(R 1 )(R 2 )O] 2 C(O)[C(R 1 )(R 2 )] 2 R 3 , -[C( R 1 )(R 2 )] 2 C(O)[OC(R 1 )(R 2 )] 2 R 3 , -[C(R 1 )(R 2 )N] 2 C(O)[C(R 1 )(R 2 )] 2 R 3 , [C(R 1 )(R 2 )N] 2 C(O)[OC(R 1 )(R 2 )] 2 R 3 , [C(R 1 )( R 2 )N] 2 C(O)[OC(R 1 )(R 2 )] 2 R 3 ,
  • the compound represented by formula II wherein X is selected from -C(O)O[C(R 1 )(R 2 )] m R 3 , -C(O)NR 4 [C (R 1 )(R 2 )] m R 3 , -[C(R 1 )(R 2 )O] m C(O)[C(R 1 )(R 2 )] n R 3 , -[C( R 1 )(R 2 )] m C(O)[OC(R 1 )(R 2 )] n R 3 or -[C(R 1 )(R 2 )] n R 5 , Y is hydrogen.
  • the compound represented by formula II wherein X is selected from -C(O)O[C(R 1 )(R 2 )] m R 3 , -C(O)NR 4 [C (R 1 )(R 2 )] m R 3 , -[C(R 1 )(R 2 )O] m C(O)[C(R 1 )(R 2 )] n R 3 , -[C( R 1 )(R 2 )] m C(O)[OC(R 1 )(R 2 )] n R 3 or -[C(R 1 )(R 2 )] n R 5 ; Y is hydrogen; m, n, o are each independently selected from 1, 2, 3, 4, 5, or 6; p, q are each independently selected from 0.
  • the compound represented by formula II wherein X is selected from -[C(R 1 )(R 2 )]C(O)[OC(R 1 )(R 2 )]R 3 , -C(O)O[C(R 1 )(R 2 )]R 3 , -C(O)NR 4 [C(R 1 )(R 2 )]R 3 , -[C(R 1 )(R 2 )O]C(O)[C(R 1 )(R 2 )]R 3 , -[C(R 1 )(R 2 )]C(O)NR 4 [C(R 1 )(R 2 ) ]R 3 or -[C(R 1 )(R 2 )]R 5 , Y is hydrogen.
  • the compound represented by formula II wherein Y is selected from -C(O)O[C(R 1 )(R 2 )] m R 3 , -C(O)NR 4 [C (R 1 )(R 2 )] m R 3 , -[C(R 1 )(R 2 )O] m C(O)[C(R 1 )(R 2 )] n R 3 , -[C( R 1 )(R 2 )] m C(O)[OC(R 1 )(R 2 )] n R 3 , -[C(R 1 )(R 2 )N] m C(O)[C(R 1 )(R 2 )] n R 3 , [C(R 1 )(R 2 )N] m C(O)[OC(R 1 )(R 2 )] n R 3 , [C(R 1 )(R 2 )N] m C(O)[OC(R 1 )
  • the compound represented by formula II wherein Y is selected from [C(R 1 )(R 2 )(O) p ] n R 5 , and R 5 is selected from C 6-10 heterocyclyl , OPO(R 6 ) 2 , OSO 2 R 6 , SR', SO 2 R', OC(O)R 7 or NR'(R”).
  • the compound represented by formula II wherein Y is selected from [C(R 1 )(R 2 )] n R 5 , and R 5 is selected from C 6-10 heterocyclyl, OPO(R 6 ) 2 , OSO 2 R 6 , SR', SO 2 R', OC(O)R 7 or NR'(R”).
  • the compound represented by formula II wherein Y is selected from [C(R 1 )(R 2 )O] n R 5 , and R 5 is selected from C 6-10 heterocyclyl, OPO( R 6 ) 2 , OSO 2 R 6 , SR', SO 2 R', OC(O)R 7 or NR'(R”).
  • the compound represented by Formula II wherein R 5 is selected from C 6-10 heterocyclyl, OPO(R 6 ) 2 , OSO 2 R 6 , SR', SO 2 R', OC(O)R 7 or NR'(R”).
  • R 6 is selected from hydrogen, C 1-6 alkyl, C 3-6 cycloalkyl, 3 to 6 membered heterocyclic group (such as piperidine), OR' or NR'(R"), R', R" are as defined in the compound represented by formula II.
  • the compound represented by formula II, wherein R'and R" are selected from hydrogen or alkyl, and the alkyl group is preferably C 1-10 alkyl, more preferably C 1-6 alkane Group, such as methyl, ethyl, propyl, isopropyl.
  • R'and R" are selected from hydrogen or alkyl, and the alkyl is preferably C 1-10 alkyl, more preferably C 1-6 alkyl, such as methyl, ethyl, propyl, isopropyl .
  • R 3 is selected from OPO(R 6 ) 2
  • R 6 is selected from hydroxyl, C 1-6 alkyl, C 3-7 cycloalkyl, C 1-6 alkoxy or 3 To 7-membered heterocyclic group.
  • R 1 or R 2 in the compound shown in II are each independently selected from hydrogen, C 1-6 alkyl, or C 3-7 cycloalkyl.
  • the compound of formula II is N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl
  • R 1 or R 2 are each independently selected from hydrogen, alkyl, cycloalkyl, heterocyclyl, aryl or heteroaryl, the alkyl, cycloalkyl, heterocyclyl, aryl or heteroaryl
  • the group is optionally selected by one or more selected from alkyl, cycloalkyl, alkoxy, hydroxyalkyl, alkenyl, alkynyl, aryl, heteroaryl, nitro, nitrile, hydroxyl, halogen, SR' , NR'(R”), COOR' or CONR'(R”);
  • R'or R" is independently selected from hydrogen, hydroxy, alkyl, alkoxy, alkenyl, acyl;
  • n 1, 2, 3 or 4.
  • R 6 in the compound of formula II is selected from
  • R'and R" are selected from hydrogen or alkyl, and the alkyl is preferably C 1-10 alkyl, more preferably C 1-6 alkyl, such as methyl, ethyl, propyl, isopropyl .
  • the compound of formula III is N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl
  • R 1 or R 2 are each independently selected from hydrogen, alkyl, cycloalkyl, heterocyclyl, aryl or heteroaryl, the alkyl, cycloalkyl, heterocyclyl, aryl or heteroaryl
  • the group is optionally selected by one or more selected from alkyl, cycloalkyl, alkoxy, hydroxyalkyl, alkenyl, alkynyl, aryl, heteroaryl, nitro, nitrile, hydroxyl, halogen, SR' , NR'(R”), COOR' or CONR'(R”);
  • R 6 is each independently selected from hydrogen, hydroxy, alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, alkoxy, hydroxyalkyl or NR'(R”), the alkyl, hydroxy Alkyl, cycloalkyl, heterocyclyl, aryl or heteroaryl is optionally selected by one or more selected from alkyl, cycloalkyl, alkoxy, hydroxyalkyl, alkenyl, alkynyl, aryl, Heteroaryl, nitro, nitrile, hydroxyl, halogen, SR', NR'(R"), COOR' or CONR'(R”) substituted;
  • R'or R" is independently selected from hydrogen, hydroxy, alkyl, alkoxy, alkenyl, acyl.
  • R 6 in the compound represented by formula IV is selected from C 1-12 alkyl (including but not limited to methyl, ethyl, propyl or isopropyl), C 3-12 ring Alkyl (including but not limited to cyclopropyl, cyclopentyl, cyclohexyl), 3 to 12 membered heterocyclyl (including but not limited to pyrrolyl), C 6-12 aryl (including but not limited to phenyl, naphthalene) Group), 3- to 12-membered heteroaryl (including but not limited to pyridine, piperidine), C 1-12 alkoxy (including but not limited to methoxy, ethoxy, propoxy or isopropoxy) , C 1-12 hydroxyalkyl or NR'(R"), the alkyl, hydroxyalkyl, cycloalkyl, heterocyclyl, aryl or heteroaryl group is optionally selected from one or more C 1 -6 alkyl, C 3-6 ring Alkyl (including
  • the compound represented by formula IV wherein said R 6 is selected from hydrogen, C 1-6 alkyl, C 3-6 cycloalkyl, 3 to 6 membered heterocyclic group (such as piperidine) , OR' or NR'(R”).
  • the compound represented by formula IV, wherein R'and R" are selected from hydrogen or alkyl, and the alkyl group is preferably C 1-10 alkyl, more preferably C 1-6 alkane Group, such as methyl, ethyl, propyl, isopropyl.
  • R 6 in the compound of formula IV is selected from
  • R'and R" are selected from hydrogen or alkyl, and the alkyl is preferably C 1-10 alkyl, more preferably C 1-6 alkyl, such as methyl, ethyl, propyl, isopropyl .
  • the compound represented by formula IV wherein said R 6 is selected from hydrogen, C 1-6 alkyl, C 3-6 cycloalkyl, 3 to 6 membered heterocyclic group (such as piperidine) , OR' or NR'(R”).
  • the compound represented by formula IV, wherein R'and R" are selected from hydrogen or alkyl, and the alkyl group is preferably C 1-10 alkyl, more preferably C 1-6 alkane Group, such as methyl, ethyl, propyl, isopropyl.
  • R 6 in the compound of formula IV is selected from
  • R'and R" are selected from hydrogen or alkyl, and the alkyl is preferably C 1-10 alkyl, more preferably C 1-6 alkyl, such as methyl, ethyl, propyl, isopropyl .
  • Typical compounds represented by formula II include but are not limited to:
  • the compounds of the present disclosure have higher solubility and better in vivo conversion than known compounds.
  • the compound of the present disclosure has a low hemolytic effect, reduces the side effects of the drug during administration, and is beneficial to improve patient administration compliance.
  • the present disclosure also provides a pharmaceutical composition, which includes at least one therapeutically effective amount of the aforementioned compound or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, diluent or excipient.
  • the hydrogen in the functional group of the compound described in the present disclosure can be deuterated to obtain the corresponding deuterated compound.
  • the deuterated compound retains the selectivity and potential equivalent to the hydrogen analog; the deuterium bond is more stable, making “ADME” namely The "toxic pharmacokinetics” are different, thereby providing clinically beneficial effects.
  • Toxic pharmacokinetics refers to the absorption, distribution, metabolism, and excretion of foreign chemicals.
  • the present disclosure also relates to the use of the compound or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition of the above-mentioned scheme in the preparation of a medicine for the treatment of a physiological disorder, disorder or disease in a patient, wherein the physiological disorder, disorder or disease is a respiratory disease , Cough, inflammatory diseases, skin disorders, eye disorders, depression, anxiety, phobias, bipolar disorder, alcohol dependence, substance abuse with a significant effect on nerves, epilepsy, nociception, psychosis, schizophrenia, Alzheimer’s Mer’s disease, dementia associated with AIDs, Towne’s disease, tension-related disorders, obsessive-compulsive/compulsive disorder, bulemia, anorexia nervosa, eating frenzy, mania, premenstrual syndrome, gastrointestinal dysfunction, Atherosclerosis, fibrotic disorders, obesity, type II diabetes, headache, neuropathic pain, post-action pain, chronic pain syndrome, bladder disorders, genitourinary disorders, vomiting or nausea. Further,
  • the pharmaceutically acceptable salt of the compound is selected from inorganic salt or organic salt.
  • the compound described in the present disclosure reacts with an acid such as trifluoroacetic acid to form a corresponding salt, and the acid is selected from but not limited to acetic acid, hydrochloric acid, salicylic acid, Malic acid, ascorbic acid, phosphoric acid, citric acid, benzoic acid or fumaric acid.
  • the compound described in the present disclosure reacts with a base such as N-methyl-D meglumine or dicyclohexylamine to form the corresponding salt, and the base is selected from but not limited to sodium, alkaline earth metals, amino acids (such as arginine, lysine) ).
  • the present disclosure also includes the same as those described in the present disclosure, but one or more atoms are replaced by an isotope-labeled compound of an atom whose atomic weight or mass number is different from the atomic weight or mass number commonly found in nature.
  • isotopes that can be incorporated into the compounds of the present application include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorus, sulfur, fluorine, iodine, and chlorine, such as 2 H, 3 H, 11 C, 13 C, 14 C, 13 N, 15 N, 15 O, 17 O, 18 O, 31 P, 32 P, 35 S, 18 F, 123 I, 125 I and 36 Cl, etc.
  • the compounds of the present disclosure may contain unnatural proportions of atomic isotopes on one or more of the atoms constituting the compound.
  • compounds can be labeled with radioisotopes, such as tritium ( 3 H), iodine-125 ( 125 I), or C-14 ( 14 C).
  • deuterated drugs can be formed by replacing hydrogen with heavy hydrogen. The bond formed by deuterium and carbon is stronger than the bond formed by ordinary hydrogen and carbon. Compared with undeuterated drugs, deuterated drugs have reduced toxic side effects and increased drug stability. , Enhance the efficacy, extend the biological half-life of drugs and other advantages. All changes in the isotopic composition of the compounds of this application, whether radioactive or not, are included in the scope of this application.
  • substitution with heavier isotopes can provide certain therapeutic advantages resulting from higher metabolic stability (for example, increased in vivo half-life or reduced dosage requirements), and therefore in certain situations
  • deuterium substitution can be partial or complete
  • partial deuterium substitution refers to the substitution of at least one hydrogen with at least one deuterium.
  • Alkyl refers to a saturated aliphatic hydrocarbon group, including straight and branched chain groups of 1 to 20 carbon atoms. An alkyl group containing 1 to 12 carbon atoms is preferred, and an alkyl group containing 1 to 6 carbon atoms is more preferred.
  • Non-limiting examples include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, sec-butyl, n-pentyl, 1,1-dimethylpropyl, 1,2-Dimethylpropyl, 2,2-dimethylpropyl, 1-ethylpropyl, 2-methylbutyl, 3-methylbutyl, and various branched isomers Wait.
  • Alkyl groups can be substituted or unsubstituted. When substituted, the substituents can be substituted at any available attachment point, preferably one or more of the following groups, independently selected from aryl and heteroaryl , Substituted by halogen.
  • alkenyl includes branched and straight chain olefins having 2 to 12 carbon atoms or olefins containing aliphatic hydrocarbon groups.
  • C 2-6 alkenyl means an alkenyl group having 2, 3, 4, 5, or 6 carbon atoms.
  • alkenyl groups include, but are not limited to, vinyl, allyl, 1-propenyl, 1-butenyl, 2-butenyl, 3-butenyl, 2-methylbut-2-enyl, 3-methylbut-1-enyl, 1-pentenyl, 3-pentenyl and 4-hexenyl.
  • cycloalkyl refers to a saturated or partially unsaturated monocyclic or polycyclic cyclic hydrocarbon substituent.
  • the cycloalkyl ring contains 3 to 20 carbon atoms, preferably 3 to 12 carbon atoms, more preferably 3 to 6 Carbon atoms.
  • Non-limiting examples of monocyclic cycloalkyl groups include cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, cyclohexadienyl, cycloheptyl, cycloheptatriene Groups, cyclooctyl, etc.; polycyclic cycloalkyls include spiro, fused, and bridged cycloalkyls.
  • the cycloalkyl ring may be fused to an aryl, heteroaryl or heterocycloalkyl ring, wherein the ring connected to the parent structure is a cycloalkyl group, non-limiting examples include indanyl, tetrahydronaphthalene Group, benzocycloheptyl group, etc. Cycloalkyl groups may be optionally substituted or unsubstituted.
  • the substituents are preferably one or more of the following groups, which are independently selected from alkyl, alkenyl, alkynyl, alkoxy, alkane Thio, alkylamino, halogen, mercapto, hydroxyl, nitro, cyano, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, cycloalkoxy, heterocycloalkoxy, cycloalkylthio , Heterocycloalkylthio, oxo, carboxy, or carboxylate.
  • groups are independently selected from alkyl, alkenyl, alkynyl, alkoxy, alkane Thio, alkylamino, halogen, mercapto, hydroxyl, nitro, cyano, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, cycloalkoxy, heterocycloalkoxy, cycloalkylthio , Heterocycloalkylthi
  • heterocyclyl refers to a saturated or partially unsaturated monocyclic or polycyclic cyclic hydrocarbon substituent which contains 3 to 20 ring atoms, one or more of which is selected from nitrogen, oxygen or S(O) m (where m is an integer from 0 to 2) heteroatoms, but does not include the ring part of -O-O-, -O-S- or -S-S-, and the remaining ring atoms are carbon. It preferably contains 3 to 12 ring atoms, of which 1 to 4 are heteroatoms; more preferably it contains 3 to 6 ring atoms.
  • Non-limiting examples of monocyclic heterocyclic groups include pyrrolidinyl, imidazolidinyl, tetrahydrofuranyl, tetrahydrothienyl, dihydroimidazolyl, dihydrofuranyl, dihydropyrazolyl, dihydropyrrolyl, piperidine Group, piperazinyl, morpholinyl, thiomorpholinyl, homopiperazinyl, etc., preferably piperidinyl and pyrrolidinyl.
  • Polycyclic heterocyclic groups include spiro, fused, and bridged heterocyclic groups.
  • the heterocyclyl ring may be fused to an aryl, heteroaryl or cycloalkyl ring, wherein the ring connected to the parent structure is a heterocyclic group, non-limiting examples thereof include:
  • the heterocyclic group may be optionally substituted or unsubstituted.
  • the substituent is preferably one or more of the following groups, which are independently selected from alkyl, alkenyl, alkynyl, alkoxy, alkane Thio, alkylamino, halogen, mercapto, hydroxyl, nitro, cyano, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, cycloalkoxy, heterocycloalkoxy, cycloalkylthio , Heterocycloalkylthio, oxo, carboxy, or carboxylate.
  • Alkynyl includes branched and straight chain alkynyl groups having 2 to 12 carbon atoms or alkene containing aliphatic hydrocarbon groups, or if the number of carbon atoms is specified, it means that specific number. For example, ethynyl, propynyl (e.g. 1-propynyl, 2-propynyl), 3-butynyl, pentynyl, hexynyl and 1-methylpent-2-ynyl.
  • aryl refers to a 6 to 14-membered all-carbon monocyclic or fused polycyclic (that is, rings sharing adjacent pairs of carbon atoms) with a conjugated ⁇ -electron system, preferably 6 to 12 members, such as benzene Base and naphthyl.
  • the aryl ring may be fused on a heteroaryl, heterocyclic or cycloalkyl ring, wherein the ring connected to the parent structure is an aryl ring, non-limiting examples of which include:
  • Aryl groups may be substituted or unsubstituted.
  • the substituents are preferably one or more of the following groups, which are independently selected from alkyl, alkenyl, alkynyl, alkoxy, alkylthio, Alkylamino, halogen, mercapto, hydroxy, nitro, cyano, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, cycloalkoxy, heterocycloalkoxy, cycloalkylthio, heterocycle Alkylthio group, carboxyl group or carboxylate group, preferably phenyl group.
  • heteroaryl refers to a heteroaromatic system containing 1 to 4 heteroatoms and 5 to 14 ring atoms, where the heteroatoms are selected from oxygen, sulfur and nitrogen.
  • the heteroaryl group is preferably 6 to 12 members, more preferably 5 members or 6 members, such as imidazolyl, furyl, thienyl, thiazolyl, pyrazolyl, oxazolyl, pyrrolyl, tetrazolyl, pyridyl, Pyrimidine, thiadiazole, pyrazinyl, etc. are preferably imidazolyl, pyrazolyl, pyrimidinyl or thiazolyl; more preferably pyrazolyl or thiazolyl.
  • the heteroaryl ring may be fused on an aryl, heterocyclic or cycloalkyl ring, wherein the ring connected to the parent structure is a heteroaryl ring, non-limiting examples of which include:
  • the heteroaryl group may be optionally substituted or unsubstituted.
  • the substituent is preferably one or more of the following groups, which are independently selected from alkyl, alkenyl, alkynyl, alkoxy, alkane Thio, alkylamino, halogen, mercapto, hydroxyl, nitro, cyano, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, cycloalkoxy, heterocycloalkoxy, cycloalkylthio , Heterocycloalkylthio, carboxyl or carboxylate.
  • alkoxy refers to -O- (alkyl) and -O- (unsubstituted cycloalkyl), where the definition of alkyl is as described above.
  • alkoxy groups include: methoxy, ethoxy, propoxy, butoxy, cyclopropoxy, cyclobutoxy, cyclopentyloxy, cyclohexyloxy.
  • the alkoxy group may be optionally substituted or unsubstituted.
  • the substituent is preferably one or more of the following groups, which are independently selected from the group consisting of alkyl, alkenyl, alkynyl, alkoxy, alkane Thio, alkylamino, halogen, mercapto, hydroxyl, nitro, cyano, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, cycloalkoxy, heterocycloalkoxy, cycloalkylthio , Heterocycloalkylthio, carboxyl or carboxylate.
  • hydroxyalkyl refers to an alkyl group substituted with a hydroxy group, where the alkyl group is as defined above.
  • haloalkyl refers to an alkyl substituted by halogen, where alkyl is as defined above.
  • deuterated alkyl refers to an alkyl group substituted with a deuterium atom, where the alkyl group is as defined above.
  • hydroxy refers to the -OH group.
  • halogen refers to fluorine, chlorine, bromine or iodine.
  • amino refers to -NH 2 .
  • cyano refers to -CN.
  • nitro refers to -NO 2 .
  • heterocyclic group optionally substituted by an alkyl group means that an alkyl group may but need not be present, and the description includes the case where the heterocyclic group is substituted by an alkyl group and the case where the heterocyclic group is not substituted by an alkyl group .
  • Substituted refers to one or more hydrogen atoms in the group, preferably up to 5, more preferably 1 to 3 hydrogen atoms, independently of each other, substituted with a corresponding number of substituents. It goes without saying that the substituents are only in their possible chemical positions, and those skilled in the art can determine (by experiment or theory) possible or impossible substitutions without too much effort. For example, an amino group or a hydroxyl group with free hydrogen may be unstable when combined with a carbon atom with an unsaturated (eg, olefinic) bond.
  • “Pharmaceutical composition” means a mixture containing one or more compounds described herein or their physiologically pharmaceutically acceptable salts or prodrugs and other chemical components, as well as other components such as physiologically pharmaceutically acceptable carriers and excipients. Shape agent. The purpose of the pharmaceutical composition is to promote the administration to the organism, which is beneficial to the absorption of the active ingredients and thus the biological activity.
  • the known starting materials in the present disclosure can be synthesized by or according to methods known in the art, or can be purchased from companies such as AcrosOrganics or Aldrich Chemical Company or obtained by the method in reference CN102775401A.
  • the structure of the compound is determined by nuclear magnetic resonance (NMR) or/and mass spectrometry (MS).
  • NMR nuclear magnetic resonance
  • MS mass spectrometry
  • the NMR shift ( ⁇ ) is given in units of 10-6 (ppm).
  • NMR is measured with BrukerAVANCE-400 nuclear magnetic instrument, the solvent is deuterated dimethyl sulfoxide (DMSO-d6), deuterated chloroform (CDCl 3 ), deuterated methanol (CD 3 OD), the internal standard is tetramethyl Silane (TMS);
  • ESI-MS was measured with a FINNIGANLCQAd (ESI) mass spectrometer (manufacturer: Thermo, model: FinniganLCQadvantageMAX), and LCMS used high performance liquid chromatography (manufacturer: Agilent, model: 1200) for gradient elution to Scanning in positive ion mode, the mass scanning range is 100 ⁇ 1500.
  • Figure 1 A trend graph of the conversion of the compound of Example 5 in human plasma.
  • the experimental methods that do not indicate specific conditions are usually in accordance with conventional conditions or in accordance with the conditions recommended by the raw material or commodity manufacturers.
  • Reagents without specific sources are conventional reagents purchased on the market.
  • the reaction solution was cooled, poured into ethyl acetate and water, separated, extracted with ethyl acetate, washed with an aqueous solution of sodium sulfite, washed with water and brine in turn, dried with anhydrous sodium sulfate, filtered, and concentrated to obtain 3.73g of yellow foam.
  • the yield was 107%.
  • compound 3 (1.95g, 2.543mmol, 1eq) was dissolved in dichloromethane (40mL) into a 100mL single-necked flask, and trifluoroacetic acid (1.45mL, 19.52mmol, 8eq) was slowly added under ice water cooling ), stirred until the reaction is complete, and concentrated to obtain 2.29 g of oily substance, and separated and purified to obtain 1.39 g of white foamy solid with a yield of 83.5%.
  • Potassium carbonate (11.7g, 84.66mmol, 8.47eq) was dissolved in water (40mL) for later use. Under the protection of N 2 , compound 1 (5.55 g, 10 mmol, 1 eq) was suspended in ethyl acetate (80 mL), the above potassium carbonate aqueous solution was added dropwise under ice-cooling, the reaction solution gradually became clear under stirring, and then Cbz-Cl was added dropwise (1.7mL, 12mmol, 1.2eq), after adding and stirring for 10min, stirring at room temperature overnight, the reaction solution was separated, extracted with ethyl acetate, combined organic phases, dried over anhydrous sodium sulfate, filtered, concentrated, column chromatography to obtain 4.3g white solid, yield 56%.
  • the target compound was synthesized by replacing Boc-L-valine with Boc-L-alanine.
  • Boc-L-proline was used instead of Boc-L-valine to synthesize the target compound.
  • pH 3.0: Phosphate buffer solution: 100ml 20mmol/L NaH 2 PO 4 , 0.1M H 3 PO 4 adjust the pH to 3.0.
  • the concentration is 160, 400, 1600, 4000, 8000, 16000, 32000ng/mL
  • the QC working solution concentration is set to 480, 1920, 25600ng/mL.
  • Example 4 The compounds of Example 4, Example 6, Example 10 and Example 11
  • the experiment is set to 7 time points of 0, 15, 30, 60, 90, 120, 180 min, and two parallel samples are set at each time point.
  • the reaction system is divided into two groups for each compound, and 75 ⁇ L of plasma is added to each compound, and 5 ⁇ L of the above preparation
  • Standard curve configuration Take the previously diluted 1600 ⁇ M solution I and acetonitrile diluted to 1.5 ⁇ M/mL solution III as the standard curve for use; the standard curve concentration is set to 0.32, 0.8, 1.6, 4.0, 8, 12, 16, 42uM; After each concentration of the standard curve is diluted, add 75 ⁇ L of plasma to 5 ⁇ L of each concentration point to make the final concentration respectively 0.02, 0.05, 0.1, 0.25, 0.75, 1.0, 1.5uM, quickly add 300 ⁇ L stop solution, centrifuge at 3700rpm 10min, take the supernatant LC-MSMS analysis. The data are shown in Table 3.
  • the plasma concentration of the compound in the example a and the plasma concentration of lorapitan after the compound in the example b is metabolized.
  • Example 4 The compounds in Example 4, Example 10 and Example 11 are relatively stable in plasma and have a longer metabolic time, but only a few of these three compounds are metabolized to lorapitan in plasma.
  • the compound in Example 6 can be metabolized to lorapitan in plasma, but from the above data, the overall metabolism in plasma is relatively small.
  • Example 2 Refer to the test method in Test Example 2 to test the metabolism of the compounds of Example 1, Example 2 and Example 8 in the plasma of mice (Mouse), rats (Rat) and humans. The data are shown in Table 4.
  • the plasma concentration of the compound in the example a and the plasma concentration of lorapitan after the compound in the example b is metabolized.
  • Example 8 can be converted into lorapitan in the plasma of mice, rats and humans, especially the conversion rate in human plasma is nearly 46%, while the compounds of Example 1 and Example 2 are in human plasma. Basically, there is no conversion to Lolapitan, or only a slight conversion.
  • the LC/MS/MS method was used to determine the drug concentration in plasma at different times after injection of the compounds of Example 1 and Example 2. Study the pharmacokinetic behavior of the compound in rats and evaluate its pharmacokinetic characteristics.
  • Intravenous bolus injection the bolus injection time is about 5 minutes, the administration dose is 2 mg/kg, the administration concentration is 0.4 mg/ml, and the administration volume is 5 ml/kg.
  • the pharmacokinetic parameters of the compounds in the example a in the rat, and the compounds in the example b are metabolized to the pharmacokinetic parameters of lorapitan in the rat.
  • Example 1 Although the compound of Example 1 is basically not metabolized to the active substance of Lorapitant in in vitro plasma, especially in human plasma, it can show excellent pharmacokinetic data of Lorapitant in rats, indicating the implementation Example 1
  • the compound has been metabolized to lorapitan in the body, and from the data of AUC 0- ⁇ , AUC 0-t and T 1/2 , the metabolic cycle, absorption and exposure level in the body after the administration of compound 1 is longer than that of lorapitan. Tan is quite.
  • Test Example 6 Pharmacokinetic test of the compound in cynomolgus monkey
  • the LC/MS/MS method was used to determine the drug concentration in plasma at different times after injection of the compound of Example 5. To study the pharmacokinetic behavior of the compound in cynomolgus monkeys and evaluate its pharmacokinetic characteristics.
  • Intravenous drip the bolus time is about 30 minutes, the dosage is 2mg/kg, the dosage is 0.4mg/ml, and the dosage is 5ml/kg.
  • Red blood cells randomly sample (EDTA whole blood) 10ml from the rabbit jugular vein or central auricular artery, put it in a conical flask of glass beads and shake for 10 minutes to remove fibrinogen and make defibrinated blood. Add about 10 times the amount of sodium chloride injection, shake well, centrifuge at 1500 rpm for 10 minutes, remove the supernatant, and wash the precipitated red blood cells with sodium chloride injection 3 times as described above until the supernatant does not show red . The obtained red blood cells were prepared into a 2% (v/v) suspension with sodium chloride injection for use.
  • test samples (the compound of Example 5 and the compound of Example 19) respectively and dissolve them in PBS (pH 7.4 or pH 5), and filter to prepare 0.4mg/ml, 0.8mg/ml, 1.2mg/ml, 1.6mg/ml and 2mg /ml, to spare.
  • test sample solution A certain amount of test sample solution is added to the above hemoglobin to test in the supernatant.
  • the solution in the test tube is clear and red, and there are no residual cells or a small amount of red blood cells at the bottom of the tube, it indicates that hemolysis has occurred; if all the red blood cells sink and the supernatant liquid is colorless and clear, it indicates that no hemolysis has occurred. If there are brown-red or red-brown flocculent precipitates in the solution, gently invert 3-5 times and still do not disperse, indicating that red blood cell aggregation may have occurred; further observation under a microscope, if visible red blood cells are aggregated.
  • the compound provided in the present disclosure uses this method to determine hemolysis.
  • the compound of Example 19 has no hemolysis at concentrations up to 2 mg/ml, and the compound of Example 5 has hemolysis at concentrations of 0.04 mg/ml and above.
  • Lorapitant emulsion (prescription: 4.4% polyethylene glycol-15 hydroxystearate, 1.1% medium chain triglyceride and 0.66% soybean oil), and prepare 0.18mg/ml with PBS. 0.09mg/ml, 0.045mg/ml, 0.023mg/ml, 0.011mg/ml, 0.056mg/ml and 0.028mg/ml for use.
  • Test Example 10 Pharmacokinetic test in cynomolgus monkey
  • the LC/MS/MS method was used to determine the drug concentration in plasma at different times after injection of the compound prepared by the method in Example 19. To study the pharmacokinetic behavior of the compound in cynomolgus monkeys and evaluate its pharmacokinetic characteristics.
  • Intravenous drip the bolus time is about 30 minutes, the dosage is 3.54mg/kg, the dosage is 2mg/ml, and the dosage is 5ml/kg.
  • blood Before administration and 5min, 0.25h, 0.5h, 1h, 2h, 4h, 6h, 8h, 10h and 24h after administration, blood shall be collected through femoral vein. Each sample shall be collected about 0.6mL. Heparin sodium is anticoagulated. After collection Put it on ice immediately. After the blood sample is collected, it is placed in a labeled centrifuge tube, and the plasma is separated by centrifugation (centrifugal force 2200g, centrifugation 10min, 2-8°C).
  • the pharmacokinetic parameters of the compounds in the example a in cynomolgus monkeys, and the pharmacokinetic parameters of the compounds in the example b are metabolized to lorapitan in cynomolgus monkeys.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Otolaryngology (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Addiction (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biotechnology (AREA)
PCT/CN2020/098460 2019-06-28 2020-06-28 神经激肽-1拮抗剂 Ceased WO2020259675A1 (zh)

Priority Applications (11)

Application Number Priority Date Filing Date Title
CN202410285183.XA CN118324811A (zh) 2019-06-28 2020-06-28 神经激肽-1拮抗剂
KR1020227003091A KR102940508B1 (ko) 2019-06-28 2020-06-28 뉴로키닌-1 길항제
MX2021015827A MX2021015827A (es) 2019-06-28 2020-06-28 Antagonista de neurokinin -1.
JP2021577929A JP7702887B2 (ja) 2019-06-28 2020-06-28 ニューロキニン－１アンタゴニスト
CA3144247A CA3144247A1 (en) 2019-06-28 2020-06-28 Neurokinin-1 antagonist
AU2020308397A AU2020308397B2 (en) 2019-06-28 2020-06-28 Neurokinin-1 antagonist
BR112021026554A BR112021026554A2 (pt) 2019-06-28 2020-06-28 Antagonista de neurocinina-1
US17/623,205 US12421260B2 (en) 2019-06-28 2020-06-28 Neurokinin-1 antagonist
CN202080040881.3A CN113905735B (zh) 2019-06-28 2020-06-28 神经激肽-1拮抗剂
EP20831251.2A EP3991730A4 (en) 2019-06-28 2020-06-28 NEUROKININ-1 ANTAGONIST
JP2025071172A JP2025111616A (ja) 2019-06-28 2025-04-23 ニューロキニン－１アンタゴニスト

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CN201910572272.1 2019-06-28
CN201910572272 2019-06-28
CN201911375262.5 2019-12-27
CN201911375262 2019-12-27

Publications (1)

Publication Number Publication Date
WO2020259675A1 true WO2020259675A1 (zh) 2020-12-30

Family

ID=74059657

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2020/098460 Ceased WO2020259675A1 (zh) 2019-06-28 2020-06-28 神经激肽-1拮抗剂

Country Status (11)

Country Link
US (1) US12421260B2 (https=)
EP (1) EP3991730A4 (https=)
JP (2) JP7702887B2 (https=)
KR (1) KR102940508B1 (https=)
CN (2) CN113905735B (https=)
AU (1) AU2020308397B2 (https=)
BR (1) BR112021026554A2 (https=)
CA (1) CA3144247A1 (https=)
MX (1) MX2021015827A (https=)
TW (1) TWI853965B (https=)
WO (1) WO2020259675A1 (https=)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114671913A (zh) * 2020-12-25 2022-06-28 上海盛迪医药有限公司 一种神经激肽-1拮抗剂的晶型及其制备方法
WO2022135549A1 (zh) * 2020-12-25 2022-06-30 上海盛迪医药有限公司 Nk1拮抗剂前药化合物与5-ht3受体拮抗剂的联用用途
WO2023134725A1 (zh) 2022-01-12 2023-07-20 江苏恒瑞医药股份有限公司 一种包含神经激肽-1拮抗剂前药化合物的药物组合物
WO2023134723A1 (zh) 2022-01-12 2023-07-20 江苏恒瑞医药股份有限公司 一种神经激肽-1拮抗剂前药化合物的晶型
WO2025044860A1 (zh) 2023-08-28 2025-03-06 科睿迪(南京)医药科技有限公司 神经激肽-1受体拮抗剂化合物

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994010165A1 (en) 1992-10-28 1994-05-11 Merck Sharp & Dohme Limited 4-arylmethyloxymethyl piperidines as tachykinin antagonists
WO1994013639A1 (en) 1992-12-14 1994-06-23 Merck Sharp & Dohme Limited 4-aminomethyl/thiomethyl/sulfonylmethyl-4-phenylpiperidines as tachykinin receptor antagonists
WO1995019344A1 (en) 1994-01-13 1995-07-20 Merck Sharp & Dohme Limited Gem-disubstituted azacyclic tachykinin antagonists
US7049320B2 (en) 2001-12-18 2006-05-23 Schering Corporation NK1 antagonists
CN1897942A (zh) * 2003-12-22 2007-01-17 先灵公司 药用组合物
CN102573475A (zh) 2009-08-14 2012-07-11 欧科生医股份有限公司 神经激肽-1拮抗剂的静脉内制剂
CN102775401A (zh) 2012-08-15 2012-11-14 青岛农业大学 一种美洛昔康的合成方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998022542A2 (en) * 1996-11-08 1998-05-28 Ikonos Corporation Chemical functionalization of surfaces
CN1678317B (zh) * 2002-07-03 2010-10-27 先灵公司 用作治疗呕吐、抑郁症、焦虑症和咳嗽的神经激肽-1(nk-1)拮抗剂的1-酰氨基-4-苯基-4-苄氧基甲基-哌啶衍生物和相关化合物
CA3123900A1 (en) * 2011-07-28 2013-01-31 Kempharm Inc. Methylphenidate-prodrugs, processes of making and using the same
CN108148060B (zh) * 2016-12-05 2020-06-19 四川科伦博泰生物医药股份有限公司 取代的杂环化合物及其衍生物，其药物组合物、制备方法及用途
CN107383008A (zh) * 2017-08-14 2017-11-24 苏州信恩医药科技有限公司 一种罗拉匹坦的合成方法

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994010165A1 (en) 1992-10-28 1994-05-11 Merck Sharp & Dohme Limited 4-arylmethyloxymethyl piperidines as tachykinin antagonists
US5620989A (en) 1992-10-28 1997-04-15 Merck Sharp & Dohme Limited 4-Arylmethyloxymethyl piperidines as tachykinin antagonsits
WO1994013639A1 (en) 1992-12-14 1994-06-23 Merck Sharp & Dohme Limited 4-aminomethyl/thiomethyl/sulfonylmethyl-4-phenylpiperidines as tachykinin receptor antagonists
WO1995019344A1 (en) 1994-01-13 1995-07-20 Merck Sharp & Dohme Limited Gem-disubstituted azacyclic tachykinin antagonists
US5760018A (en) 1994-01-13 1998-06-02 Merck Sharp & Dohme Ltd. Gem-disubstituted azacyclic tachykinin antagonists
US7049320B2 (en) 2001-12-18 2006-05-23 Schering Corporation NK1 antagonists
CN1897942A (zh) * 2003-12-22 2007-01-17 先灵公司 药用组合物
CN102573475A (zh) 2009-08-14 2012-07-11 欧科生医股份有限公司 神经激肽-1拮抗剂的静脉内制剂
US9101615B2 (en) 2009-08-14 2015-08-11 Opko Health, Inc. Intravenous formulations of neurokinin-1 antagonists
CN102775401A (zh) 2012-08-15 2012-11-14 青岛农业大学 一种美洛昔康的合成方法

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
ROGIERS ET AL., TETRAHEDRON, vol. 57, 2001, pages 8971 - 8981
ROMBOUTS ET AL., TETRAHEDRON LETTERS, vol. 42, 2001, pages 7397 - 7399
WU ET AL., TETRAHEDRON, vol. 56, 2000, pages 3043 - 3051

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114671913A (zh) * 2020-12-25 2022-06-28 上海盛迪医药有限公司 一种神经激肽-1拮抗剂的晶型及其制备方法
WO2022135549A1 (zh) * 2020-12-25 2022-06-30 上海盛迪医药有限公司 Nk1拮抗剂前药化合物与5-ht3受体拮抗剂的联用用途
WO2023134725A1 (zh) 2022-01-12 2023-07-20 江苏恒瑞医药股份有限公司 一种包含神经激肽-1拮抗剂前药化合物的药物组合物
WO2023134723A1 (zh) 2022-01-12 2023-07-20 江苏恒瑞医药股份有限公司 一种神经激肽-1拮抗剂前药化合物的晶型
EP4464320A4 (en) * 2022-01-12 2025-05-14 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Pharmaceutical composition comprising neurokinin-1 antagonist prodrug compound
WO2025044860A1 (zh) 2023-08-28 2025-03-06 科睿迪(南京)医药科技有限公司 神经激肽-1受体拮抗剂化合物

Also Published As

Publication number Publication date
CN113905735B (zh) 2024-03-15
US12421260B2 (en) 2025-09-23
US20220380393A1 (en) 2022-12-01
TW202115064A (zh) 2021-04-16
CN113905735A (zh) 2022-01-07
MX2021015827A (es) 2022-04-11
AU2020308397B2 (en) 2026-01-08
KR20220054287A (ko) 2022-05-02
CA3144247A1 (en) 2020-12-30
JP7702887B2 (ja) 2025-07-04
EP3991730A4 (en) 2023-08-09
TWI853965B (zh) 2024-09-01
CN118324811A (zh) 2024-07-12
BR112021026554A2 (pt) 2022-05-24
EP3991730A1 (en) 2022-05-04
JP2025111616A (ja) 2025-07-30
AU2020308397A1 (en) 2022-02-17
JP2022539570A (ja) 2022-09-12
KR102940508B1 (ko) 2026-03-16

Similar Documents

Publication Publication Date Title
TWI853965B (zh) 神經激肽-1拮抗劑
JP7083087B2 (ja) それに関連する障害の治療または予防に有用なβ－３アドレナリン受容体調節剤
CN114685488A (zh) 作为sos1抑制剂的化合物及其应用
WO2023139534A1 (en) Spirocyclic piperidinyl derivatives as complement factor b inhibitors and uses thereof
WO2021047622A1 (zh) 吡啶氮氧化合物及其制备方法和用途
TWI846774B (zh) 作為免疫調節的芳環衍生物及其製備方法和應用
BR112012020693B1 (pt) Derivados de ciclobutano e metilciclobutano como inibidores de janus quinase e composição que os compreende
CN103524421B (zh) 新型萘脲类衍生物及其医疗应用
JP2023543069A (ja) ピリジニルフェニル化合物の結晶及びその製造方法
CN102372701A (zh) 氮杂双环己烷类衍生物、其制备方法及其在医药上的应用
TWI896250B (zh) 螺環烯基類或氮雜烯基類化合物及其藥物組合物、製備方法和用途
WO2020135454A1 (zh) 一类类固醇化合物及其用途
TW202128660A (zh) 稠合吡啶環衍生物、其製備方法及其在醫藥上的應用
RU2827715C2 (ru) Антагонист нейрокинина-1
HK40064843B (zh) 神经激肽-1拮抗剂
HK40064843A (en) Neurokinin-1 antagonist
KR20250093575A (ko) Kras g12d 억제제 및 그 응용
CN109422668B (zh) 一种长效雷沙吉兰前药及其制备方法和用途
TW202306952A (zh) 含三并環類衍生物調節劑、其製備方法和應用
WO2015074605A1 (zh) 一种紫杉烷类化合物、其制备方法和用途
HK40117267A (zh) 新颖咪唑并吡啶和吡唑并吡啶磺醯胺衍生物
WO2025044860A1 (zh) 神经激肽-1受体拮抗剂化合物
WO2024149150A1 (zh) 氘代吡唑并嘧啶衍生物及其制备方法和药物组合物、结合物及应用
WO2025102600A1 (zh) 一种新型杂环化合物
CN121057736A (zh) 大环杂环化合物及其用途

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 20831251

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 3144247

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2021577929

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112021026554

Country of ref document: BR

WWE Wipo information: entry into national phase

Ref document number: 2020831251

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2020308397

Country of ref document: AU

Date of ref document: 20200628

Kind code of ref document: A

REG Reference to national code

Ref country code: BR

Ref legal event code: B01E

Ref document number: 112021026554

Country of ref document: BR

Free format text: APRESENTAR, EM ATE 60 (SESSENTA) DIAS, A TRADUCAO SIMPLES DA FOLHA DE ROSTO DA CERTIDAO DE DEPOSITO DAS PRIORIDADES CN 201910272272.1 DE 28/06/2019 E CN 2019113752612.5 DE 27/12/2019 OU DECLARACAO CONTENDO, OBRIGATORIAMENTE, TODOS OS DADOS IDENTIFICADORES DESTAS CONFORME O ART. 15 DA PORTARIA 39/2021. O DOCUMENTO APRESENTADO NAO ESTA TRADUZIDO

ENP Entry into the national phase

Ref document number: 112021026554

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20211227

WWG Wipo information: grant in national office

Ref document number: 17623205

Country of ref document: US